Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial

BACKGROUND: Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody targeting VEGF-A. It is currently used with chemotherapy as the first- or second-line therapy in metastatic colorectal cancer. Previous studies have showed that anti-angiogenic agents decrease capillary density....

Descripción completa

Detalles Bibliográficos
Autores principales: Fumet, Jean-David, Bertaut, Aurélie, Bengrine, Leila, Lapierre, Patricia, Vincent, Julie, Ghiringhelli, François, Falvo, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849157/
https://www.ncbi.nlm.nih.gov/pubmed/29560093
http://dx.doi.org/10.18632/oncotarget.22822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849157/
https://www.ncbi.nlm.nih.gov/pubmed/29560093
http://dx.doi.org/10.18632/oncotarget.22822

Ejemplares similares